SIH Partners’s Trevi Therapeutics TRVI Stock Holding History

SIH Partners’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,001	Closed	-$119K	–	421
2026 Q1	$119K	Buy	+10,001	New	+$112K	﹤0.01%	280

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

SIH Partners's TRVI Position: Q2 2026 in Review

SIH Partners sold out of Trevi Therapeutics (TRVI) in Q2 2026, closing a stake of 10,001 shares — an estimated $119K sold.

SIH Partners first reported a position in TRVI in Q1 2026 and held it in 1 quarter. The position peaked at $119K in Q1 2026. 219 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

SIH Partners reported no remaining Trevi Therapeutics position as of Q2 2026 after selling out during the quarter.
SIH Partners sold 10,001 Trevi Therapeutics shares in Q2 2026, an estimated $119K.
SIH Partners first reported a position in Trevi Therapeutics in Q1 2026 and held it in 1 quarter.
SIH Partners's Trevi Therapeutics position peaked at $119K in Q1 2026.
219 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on SIH Partners's 13F filing for Q2 2026, filed 14 Aug 2026.